By preventing illness, disability, premature death, lost wages, and other costs, this modeling study found that vaccines against ten pathogens averted $828.5 billion of economic burden in 94 low- and middle-income countries between 2021 and 2030. Immunization programs provided a high return on investment (ROI), with projections for net benefits of vaccine programs estimated at $1,445.3 billion (using a cost-of-illness approach) and $3,371.5 billion (using a value-of-a-statistical-life approach) from 2011 to 2030. For every $1 invested in immunization, there was a return on investment of $20 using cost-of-illness and $52 using a value-of-a-statistical-life approach.
Full Citation:
Sim SY, Watts E, Constenla D et al.. 2020. Return On Investment From Immunization Against 10 Pathogens In 94 Low- And Middle-Income Countries, 2011–30. Health Affairs. 39(8).
Title of Article: Return On Investment From Immunization Against 10 Pathogens In 94 Low- And Middle-Income Countries, 2011–30
Author(s): Sim SY, Watts E, Constenla D et al.
Publication Year: 2020
Publication Name: Health Affairs
Publication Volume: 39(8)
Publication Source URL: https://pubmed.ncbi.nlm.nih.gov/32744930/
DOI (Digital Object Identifier): 10.1377/hlthaff.2020.00103
Topics: Economics & Return on Investment
Disease Vaccines: Haemophilus lnfluenzae type b (Hib) | Hepatitis (A & B) | Human papillomavirus (HPV) | Japanese encephalitis | Measles | Meningitis | Pneumonia | Rotavirus | Rubella | Yellow fever
Immunization Terms: Return on investment
Countries: Global